Retinal imaging system seeks to improve our vision of Alzheimer’s disease

A novel, noninvasive eye imaging system able to detect pathological markers of Alzheimer’s disease (AD) has been presented in a proof-of-concept study from researchers at Cedars-Sinai Medical Center (CA, USA) and NeuroVision LLC (CA, USA). The technology scans the retina for beta-amyloid protein (Aβ) deposits, which represent the status of deposits in the brain. Previous research has suggested that Aβ accumulation is an early event in disease development, highlighting its potential as an early biomarker suitable for screening. Currently, Aβ is only detectable by invasive and expensive processes such as cerebrospinal fluid analysis or PET scans. These techniques are impractical...